Brachytherapy Companies

*Disclaimer: List of key companies in no particular orderLatest Brachytherapy Companies Update

• 
  Sep 2023: Point Biopharma Global and Eckert & Ziegler have signed a contract to deliver carrier-free lutetium-177 (Lu-177). With a total sales volume exceeding 100 million euros ($105.6 million U.S.), the agreement has ten years. The provision of Lu-177, according to Eckert & Ziegler, is contingent upon the business's own Lu-177 being successfully validated using the targeted chemicals. Meanwhile, there are other clinical candidates based on Lu-177 in Point's supply pipeline, one of which is envisioned to treat metastatic castration-resistant prostate cancer. The businesses stated that the agreement's estimated sales volume is contingent upon a clinical candidate based on Lu-177 receiving regulatory approval in the future. According to Eckert & Ziegler, it intends to invest roughly 10 million euros ($10.6 million) in its Wilmington, Massachusetts location

• 
  Feb 2023: The privately held Viewpoint Molecular Targeting, Inc. and Isoray, Inc., a pioneer in seed brachytherapy and medical technology firm, have completed their merger. The merged businesses aim to develop cancer treatments using radiation, radiopharmaceuticals, and imaging methods to give precise, targeted medicinal dosages directly to the tumor sites of cancer patients. Our combination with Viewpoint Molecular Targeting demonstrates our dedication to expanding on our shared vision of treating diseases from the inside out while offering each patient individualized targeted treatment options.

• IsoAid (US)


• IsoRay Medical Inc. (US)


• R. Bard Inc. (US)


• Eckert & Ziegler (Germany)


• Varian Medical System Inc. (US)


• Argon Medical Devices Inc. (US)